abstract
- OBJECTIVE: To report the results of the Mexican Delphi consensus on the indication of favipiravir in patients with COVID-19. METHODOLOGY: Based on the Delphi method, a group of specialists developed a questionnaire with questions regarding the benefit or otherwise of treatment with favipiravir for patients with COVID-19. This was done after diagnosis, identification of risk factors and comorbidities, and search for the ideal patient to receive the drug under study. Patients were followed up with laboratory and imaging studies. RESULTS: The consensus was concluded with 15 recommendations for the indication of favipiravir in patients with COVID-19 infection in Mexico for prescription at any level of medical care. CONCLUSIONS: Favipiravir is a good treatment option for patients with COVID-19 pneumonia and comorbidities with strong clinical results in reducing symptoms and preventing disease progression in the short term. The data from this study show that there is a consensus on the need to prescribe favipiravir to patients with COVID-19 infection and at risk of disease progression. The consensus fulfills the established goals of having an initial document of evidence, by recommendation, regarding the indication of favipiravir for patients with COVID-19 infection.